Articles



Bridging Quality and Voice: The Crucial Intersection
for Patient-Centric Pharmaceutical Services

Schey C1, Bittcher G2

  1. SHOUT Sàrl, Switzerland
  2. Godela Health, Switzerland

In today’s rapidly evolving pharmaceutical landscape, the call for patient-centricity is louder and clearer than ever. Patients are no longer passive recipients of care but active partners whose insights and experiences are invaluable. Two distinct yet complementary approaches exemplify this paradigm shift: the meticulous rigor of clinical trial compliance and in-depth authentic, empowered patient advocacy.

Good Clinical Practice (GCP) ensures that clinical research not only meets stringent regulatory standards but also prioritizes participant welfare. The role of GCP is foundational in building ethically sound, compliant clinical trials that serve as the backbone of safe and effective pharmaceutical development. Through expert guidance on trial processes, documentation, and regulatory compliance, GCP upholds the integrity of medical research with the patient’s safety and rights at the forefront.

Advocacy that amplifies the voices of those living with rare conditions embodies and wholly represents the patients and their families. By supporting patient advisory groups and facilitating meaningful collaboration between patients and the healthcare industry, advocacy ensures that patient perspectives actively shape healthcare initiatives. This brings lived experiences to life highlighting cultural nuances and patient priorities, transforming them from afterthoughts into driving forces behind decision-making.

The intersection of these two approaches – structured, quality-driven clinical research and authentic, patient-led engagement – is where true patient-centric pharmaceutical services emerge. Neither can stand alone if the goal is to develop treatments that are not only scientifically robust but also genuinely aligned with patient needs. This is exceptionally important in the research and development of treatments for rare diseases, where the patient population is small, there are heterogenous manifestations of disease, significant unmet medical need, and often complex clinical trial design.

This synergy responds to a pressing challenge: how to maintain rigorous, regulatory-compliant processes while embracing the complexity and diversity of patient experiences. Clinical trials must transcend checkpoints and documentation to become collaborative journeys where patients contribute to shaping outcomes that matter most to them. Meanwhile, patient advisory mechanisms need the structure and oversight provided by GCP excellence to ensure their input meaningfully influences research quality and ethical standards.

Embracing this intersection calls for pharmaceutical innovators, regulators, and patient advocates to forge integrated pathways—where compliance frameworks and patient insights coalesce seamlessly. This ensures medicines are developed in a way that respects and incorporates patient realities, fostering trust, improving adherence, and ultimately enhancing health outcomes.

Achieving the Intersectionality

Pharmaceutical companies can meet the intersectionality of rigorous clinical compliance and authentic patient engagement by adopting a comprehensive, systematic approach focused on true patient-centricity. Key actions should include:

  • Align the internal company structure and culture to embed patient-centric values across functions (R&D, medical affairs, commercial) and foster leadership that champions patient engagement as a strategic priority, ensuring organizational commitment and resource allocation while retaining the GCP structure and guidelines.
  • Define and establish dedicated patient engagement. Many health conditions are represented by patient advisory groups (PAGs) that provide firsthand knowledge about patients’ experiences, daily challenges, and unmet needs. This input helps shape relevant research questions, trial designs, endpoints, and study protocols that reflect real-world priorities for GCP.
  • Include and engage with patients from different backgrounds, disease stages, and experiences to ensure feedback reflects the broad spectrum of patient needs and priorities, enhancing relevance and inclusivity.
  • Remove the barriers to study inclusion by addressing technical, logistical, and interpersonal challenges upfront by providing dedicated support, flexible involvement options, and skilled moderation allowing for accessible engagement for patients.
  • Integrate patient engagement into routine processes so that patient involvement is a consistent part of clinical research, development, and commercialization, not a one-off activity. Structured advisory boards, ongoing forums, and periodic surveys support continuous dialogue.
  • Identify patient subgroups for targeted engagement, allowing deeper insights and tailored approaches. Technology-enabled platforms can facilitate efficient management and measurement of engagement efforts.
  • Close the loop with impact reporting. In the past, patients that have contributed to study development have often been left without any final answers. By demonstrating to patients how their feedback shapes decisions, fosters improvements, and creates value, the pharmaceutical company can further reinforce patient empowerment and loyalty.

The intersection of GCP and advocacy symbolizes the evolving future of pharma: one where quality assurance and patient empowerment intersect to create healthcare that is not only effective but also truly patient-centered. In this shared space, the promise of personalized, ethical, and impactful pharmaceutical services can be fully realized resulting in benefits for the companies developing treatments, patients, their families, and the wider society.

References

  1. ExtendMed. The Pharma Guide to Patient Centricity in 2025: 7 Insider Strategies. 2024. Accessed September 2025: https://www.extendmed.com/news-and-resources/patient-centricity
  2. International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use. ICH Harmonised Guideline: Guideline For Good Clinical Practice. E6(R3). 2025. Accessed September 2025: https://database.ich.org/sites/default/files/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf
  3. European Medicines Agency. ICH E6 Good clinical practice – Scientific guideline. 2025. Accessed September 2025: https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline
  4. Clinical Trials Transformation Initiative (CTTI). CTTI Recommendations: Patient Group Engagement. 2015. Accessed September 2025: https://ctti-clinicaltrials.org/wp-content/uploads/2021/06/CTTI_Patient_Group_Engagement_Recs.pdf
  5. Frost J; Widening Engagement Patient Advisory Group; Mandizha J, Jones S, van den Dungen C, Asare L, Pope C. Widening Patient Engagement for Rare Disease Drug Trials: The Perspectives of Patients With Idiopathic Pulmonary Fibrosis on Participating in Clinical Drug Trials and Drug Trial Design. Health Expect. 2025 Apr;28(2):e70260. doi: 10.1111/hex.70260
  6. World Health Organization. Patient Engagement. 2016. Accessed September 2025: https://iris.who.int/bitstream/handle/10665/252269/9789241511629-eng.pdf
  7. Eurordis. Involving those who matter most: Improving patient engagement in the development of medicines. 2022. Accessed September 2025: https://www.eurordis.org/patient-engagement-in-medicines-development/
  8. OECD Publications. Patient engagement for patient safety. Accessed September 2025: https://www.oecd.org/en/publications/2023/09/patient-engagement-for-patient-safety_1c48c99b.html
  9. Cox GF. The art and science of choosing efficacy endpoints for rare disease clinical trials. Am J Med Genet A. 2018 Apr;176(4):759-772. doi: 10.1002/ajmg.a.38629.
  10. Deloitte. Unlocking the Future of Customer Engagement in Pharma. 2025. Full report on file. Accessed September 2025: https://www.deloitte.com/ch/en/Industries/life-sciences-health-care/analysis/unlocking-the-future-of-customer-engagement-in-pharma.html
  11. Patient Focused Medicines Development (PFMD). PFMD Strategic Approach. 2021. Accessed September 2025: https://patientfocusedmedicine.org/about-pfmd/
  12. European Joint Programme Rare Diseases. Short Gide on Patient Partnerships in Rare Disease Research Projects. 2020. Accessed September 2025: https://www.ejprarediseases.org/wp-content/uploads/2021/03/SHORT-GUIDE-ON-PATIENT-PARTNERSHIPS-IN-RARE-DISEASE-RESEARCH-PROJECTS.pdf
  13. Every Life Foundation. Rare Disease PFDD. Guide to Patient Involvement in Rare Disease Therapy Development. 2019. Accessed September 2025: https://everylifefoundation.org/wp-content/uploads/2022/01/Guide-to-Patient-Involvement-FINAL-COMPLETE-GUIDE-Rev.pdf
  14. INVOLVE. Briefing notes for researchers : involving the public in NHS, public health and social care research. 2012. Accessed September 2025: